Logo
x

Search

Subscribe Now
UCB’s Bimzelx (Bimekizumab-bkzx) Secures the US FDA’s Approval for Treating Moderate to Severe Hidradenitis Suppurativa (HS)

UCB’s Bimzelx (Bimekizumab-bkzx) Secures the US FDA’s Approval for Treating Moderate to Severe Hidradenitis Suppurativa (HS)

  • November 21, 2024
Jazz Pharmaceuticals’ Ziihera (Zanidatamab-hrii) Secures the US FDA’s Accelerated Approval to Treat HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC)

Jazz Pharmaceuticals’ Ziihera (Zanidatamab-hrii) Secures the US FDA’s Accelerated Approval to Treat HER2-Positive (IHC 3+) Biliary...

  • November 21, 2024
Pharmanovia Collaborates with Lindis Biotech to Commercialize Catumaxomab for Treating Malignant Ascites

Pharmanovia Collaborates with Lindis Biotech to Commercialize Catumaxomab for Treating Malignant Ascites

  • November 20, 2024
Sangamo Therapeutics Receives the US FDA’s IND Approval for ST-503 to Treat Idiopathic Small Fiber Neuropathy

Sangamo Therapeutics Receives the US FDA’s IND Approval for ST-503 to Treat Idiopathic Small Fiber Neuropathy

  • November 20, 2024
Pfizer Reports the EC’s Approval of Hympavzi (Marstacimab) to Treat Hemophilia A/B without Inhibitors in Adults and Adolescents

Pfizer Reports the EC’s Approval of Hympavzi (Marstacimab) to Treat Hemophilia A/B without Inhibitors in Adults and Adolescents

  • November 20, 2024
Novo Nordisk Highlights the Part 1 Results from P-III (ESSENCE) Study of Semaglutide to Treat MASH at AASLD 2024 - The Liver Meeting

Novo Nordisk Highlights the Part 1 Results from P-III (ESSENCE) Study of Semaglutide to Treat MASH at AASLD 2024 - The Liver Meeti...

  • November 20, 2024
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.